Cleared Traditional

K243013 - LIAISON PLEX Gram-Negative Blood Culture Assay (FDA 510(k) Clearance)

Apr 2025
Decision
203d
Days
Class 2
Risk

K243013 is an FDA 510(k) clearance for the LIAISON PLEX Gram-Negative Blood Culture Assay. This device is classified as a Gram-negative Bacteria And Associated Resistance Markers (Class II - Special Controls, product code PEN).

Submitted by Luminex Corporation (Northbrook, US). The FDA issued a Cleared decision on April 18, 2025, 203 days after receiving the submission on September 27, 2024.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3365. A Qualitative Multiplexed In Vitro Diagnostic Device To Detect And Identify Gram-negative Bacteria And Resistance Markers In Positive Blood Cultures..

Submission Details

510(k) Number K243013 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 27, 2024
Decision Date April 18, 2025
Days to Decision 203 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code PEN - Gram-negative Bacteria And Associated Resistance Markers
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3365
Definition A Qualitative Multiplexed In Vitro Diagnostic Device To Detect And Identify Gram-negative Bacteria And Resistance Markers In Positive Blood Cultures.